CLINICAL TRIALS PROFILE FOR PROBALAN
✉ Email this page to a colleague
All Clinical Trials for PROBALAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00334529 ↗ | Alternative Oseltamivir Dosing Strategies | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2006-06-05 | This study will determine if oseltamivir (Tamiflu(Registered Trademark)) is safe and effective given less frequently than the currently prescribed dose of twice a day for 5 days to people who have the flu, and once a day for up to 6 weeks in people who have been exposed to someone else with flu and want to prevent getting it themselves. This study will see if the drug can be given once every other day instead of daily if given with another medication called probenecid (Benemid(Registered Trademark) or Probalan(Registered Trademark)). Healthy people 18 years of age and older may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests. Participants are randomly assigned to one of the following regimens for 2 weeks: 1) 75 milligrams (mg) of oseltamivir once a day; 2) 75 mg of oseltamivir once every other day plus 500 mg probenecid four times a day; or 3) 75 mg of oseltamivir once every other day plus 500 mg probenecid twice a day. All medications are taken by mouth. On study day 0, subjects have the following baseline procedures: measurement of vital signs, review of medical and medication history, physical examination, blood draw and urine test. They also receive the first dose of oseltamivir or oseltamivir and probenecid. In addition, they undergo the following procedures as follows: - Days 1 and 4: Vital signs; review of clinical symptoms, side effects and medications taken; urine testing and blood draw. - Day 8: Same as day 1 plus count of study medication. - Day 14: Same as day 8 plus pharmacokinetic study to measure the amount of oseltamivir and probenecid in the blood. For this test, a catheter is inserted into an arm vein and blood samples are collected through the catheter before taking the study medications, at the time the medications are taken, and again at 15 minutes, 30 minutes, 45 minutes and 1, 1.5, 2, 4, 8 and 12 hours after the medication is taken. The catheter is then removed. This is the last day to take the study medication. - Day 15: Blood draw for 24-hour (post medication) blood sample. - Day 16: Blood draw for 48-hour (post medication) blood sample. - Days 21 and 28: Same as day 1. |
| NCT03296800 ↗ | Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects | Completed | Theracos | Phase 1 | 2017-09-27 | The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin. The study is to evaluate how safe the study drug is and how well the study drug is tolerated when taken with probenecid, verapamil or rifampin. |
| NCT04218357 ↗ | Probenecid as Medication for Alcohol Use Disorder | Recruiting | Brown University | Phase 1 | 2020-12-02 | The design is a randomized, within-subject, crossover, double-blind, placebo-controlled human alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two laboratory sessions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROBALAN
Condition Name
Clinical Trial Locations for PROBALAN
Trials by Country
Clinical Trial Progress for PROBALAN
Clinical Trial Phase
Clinical Trial Sponsors for PROBALAN
Sponsor Name
